Beckway Trailblazers recently delivered scheduling and production improvements at a $200M healthcare research company. The team achieved a 29% reduction in the backlog of samples to be analyzed, leading to the recognition of an additional $400K of revenue. They also accelerated the adoption of automation in bioanalysis, leading to a 50% increase in the utilization of automation equipment, and the potential for a 20-30% increase in overall bioanalysis throughput and halving the failure rate. For more information, contact Beckway’s IBP practice lead, Dale Gulick, at dgulick@beckway.com.
close
